147 related articles for article (PubMed ID: 23161636)
1. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I.
Sayahi H; Pugliese KM; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
Chem Biodivers; 2012 Nov; 9(11):2582-96. PubMed ID: 23161636
[TBL] [Abstract][Full Text] [Related]
2. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
3. Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.
Sayahi H; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
Bioorg Med Chem Lett; 2011 Aug; 21(16):4804-7. PubMed ID: 21775138
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
Ngo SC; Zimhony O; Chung WJ; Sayahi H; Jacobs WR; Welch JT
Antimicrob Agents Chemother; 2007 Jul; 51(7):2430-5. PubMed ID: 17485499
[TBL] [Abstract][Full Text] [Related]
5. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
[TBL] [Abstract][Full Text] [Related]
6. Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
Baughn AD; Deng J; Vilchèze C; Riestra A; Welch JT; Jacobs WR; Zimhony O
Antimicrob Agents Chemother; 2010 Dec; 54(12):5323-8. PubMed ID: 20876380
[TBL] [Abstract][Full Text] [Related]
7. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance mechanism of PncA in Mycobacterium tuberculosis.
Rajendran V; Sethumadhavan R
J Biomol Struct Dyn; 2014; 32(2):209-21. PubMed ID: 23383724
[TBL] [Abstract][Full Text] [Related]
9. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
[TBL] [Abstract][Full Text] [Related]
10. In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
Gopal P; Tasneen R; Yee M; Lanoix JP; Sarathy J; Rasic G; Li L; Dartois V; Nuermberger E; Dick T
ACS Infect Dis; 2017 Jul; 3(7):492-501. PubMed ID: 28271875
[TBL] [Abstract][Full Text] [Related]
11. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
12. Pyrazinamide triggers degradation of its target aspartate decarboxylase.
Gopal P; Sarathy JP; Yee M; Ragunathan P; Shin J; Bhushan S; Zhu J; Akopian T; Kandror O; Lim TK; Gengenbacher M; Lin Q; Rubin EJ; Grüber G; Dick T
Nat Commun; 2020 Apr; 11(1):1661. PubMed ID: 32245967
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Aragón LM; Garrigó M; Moreno C; Español M; Coll P
J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
[TBL] [Abstract][Full Text] [Related]
14. Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan.
Miyagi C; Yamane N; Yogesh B; Ano H; Takashima T
Diagn Microbiol Infect Dis; 2004 Feb; 48(2):111-6. PubMed ID: 14972380
[TBL] [Abstract][Full Text] [Related]
15. [Nutrient starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis].
Chen ZF; Huang Q; Li YY; Zhang Y; Ren Y; Li KS; Fu ZJ; Xu SQ
Zhonghua Jie He He Hu Xi Za Zhi; 2007 May; 30(5):359-62. PubMed ID: 17651643
[TBL] [Abstract][Full Text] [Related]
16. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
[TBL] [Abstract][Full Text] [Related]
17. [Pyrazinamide monoresistant Mycobacterium tuberculosis in Manisa region, Turkey].
Ozkütük N; Ecemiş T; Sürücüoğlu S
Mikrobiyol Bul; 2008 Oct; 42(4):585-90. PubMed ID: 19149079
[TBL] [Abstract][Full Text] [Related]
18. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
[TBL] [Abstract][Full Text] [Related]
19. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
[TBL] [Abstract][Full Text] [Related]
20. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.
Boshoff HI; Mizrahi V; Barry CE
J Bacteriol; 2002 Apr; 184(8):2167-72. PubMed ID: 11914348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
